MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

Core Insights - MeiraGTx Holdings plc is a genetic medicines biotech focused on late-stage pipeline development and has capabilities for end-to-end GMP manufacturing [1] Group 1: Company Overview - The main drug candidate of MeiraGTx is AAV-AIPL1, which targets congenital blindness and is progressing towards exceptional-circumstances filings [1]